8-K: Xtant Medical Secures $5 Million in Private Placement to Bolster Working Capital

Xtant Medical Holdings, Inc. has entered into a securities purchase agreement for a $5 million private placement with an existing institutional investor to fund working capital and general corporate purposes.

Summary

• Xtant Medical Holdings, Inc. has agreed to a private placement of 7,812,500 shares of common stock at $0.64 per share.
• The gross proceeds from this placement are expected to be $5.0 million before deducting fees and expenses.
• The company intends to use the net proceeds for working capital and other general corporate purposes.
• The closing of the private placement is anticipated to occur around August 9, 2024, pending customary closing conditions.
• The company has agreed to file a shelf resale registration statement with the SEC within 30 days of closing to register the resale of the shares.
• The company will use commercially reasonable best efforts to have the registration statement declared effective within 60 days of closing, or 90 days if reviewed by the SEC.
• Failure to meet filing deadlines or keep the registration effective will result in liquidated damages to the investor.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company is securing necessary funding, but there are some restrictions and potential penalties associated with the agreement.

Positives

• The private placement provides a significant capital injection of $5 million to support working capital and general corporate needs.
• The company has secured funding from an existing institutional investor, indicating continued confidence in the company.
• The company is taking steps to ensure the shares can be resold by the investor through a registration statement.

Negatives

• The company will incur offering fees and expenses, reducing the net proceeds from the $5 million gross amount.
• The company is subject to restrictions on issuing further securities for a period of time after the resale registration statement is effective.
• The company will be required to pay liquidated damages if it fails to meet the filing deadlines or keep the resale registration statement effective.

Risks

• The closing of the private placement is subject to customary closing conditions, which may not be met.
• The company may face challenges in meeting the deadlines for filing and getting the resale registration statement effective.
• The company is subject to a 90-day restriction on issuing certain securities and a 6-month restriction on variable rate transactions after the resale registration statement is effective.
• The company may be subject to liquidated damages if it fails to meet the registration deadlines or keep the registration statement effective.

Future Outlook

The company expects to use the net proceeds from the private placement for working capital and other general corporate purposes. The company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issued in the private placement.

Management Comments

• The company expects to use the net proceeds from the private placement for working capital and other general corporate purposes.

Industry Context

This private placement is a common method for companies to raise capital, particularly in the medical technology sector where funding is often needed for research, development, and commercialization. The use of an existing institutional investor suggests a level of confidence in the company's prospects.

Comparison to Industry Standards

• Private placements are a standard method for raising capital in the medical technology industry, especially for companies that are not yet profitable or are in a growth phase.
• The terms of the agreement, including the lock-up periods and registration rights, are typical for this type of transaction.
• The size of the placement, $5 million, is relatively small compared to some larger capital raises in the sector, but is appropriate for a company of Xtant Medical's size and stage.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• The company will have additional capital to support operations and growth.
• The institutional investor will gain a larger stake in the company.

Next Steps

• The company will close the private placement on or about August 9, 2024.
• The company will file a shelf resale registration statement with the SEC within 30 days of closing.
• The company will work to have the resale registration statement declared effective by the SEC.

Key Dates

Keywords

private placement, securities purchase agreement, common stock, registration rights, working capital, institutional investor, shelf registration, resale registration, liquidated damages, XTNT